Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity

Antiviral Therapy

Volumn 22, Issue 2, 2017, Pages 163-168

  Pérez Matute, Patricia ^a   Pichel, José G ^a   Iñiguez, María ^a   Recio Fernández, Emma ^a   Pérez Martínez, Laura ^a   Torrens, Raquel ^a   Blanco, José Ramón ^a   Oteo, José Antonio ^a  

^a CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; JANUS KINASE; MARAVIROC; TUMOR NECROSIS FACTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARDIOTROPHIN 1; CCL2 PROTEIN, MOUSE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIAZOLE DERIVATIVE;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; EPIDIDYMIS FAT; INSULIN RESISTANCE; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; UPREGULATION; WEIGHT GAIN; ANIMAL; BODY WEIGHT GAIN; C57BL MOUSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIPID DIET; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; ANTI-HIV AGENTS; CCR5 RECEPTOR ANTAGONISTS; CHEMOKINE CCL2; CYCLOHEXANES; CYTOKINES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; INSULIN RESISTANCE; MACROPHAGES; MALE; MAP KINASE KINASE 4; MARAVIROC; MICE; MICE, INBRED C57BL; OBESITY; TRIAZOLES; WEIGHT GAIN;

EID: 85019939229     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3099     Document Type: Article

References (25)

1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382:1525-1533.
2. Calvo M, Martinez E. Update on metabolic issues in HIV patients. Curr Opin HIV AIDS 2014; 9:332-339.
3. Koethe JR, Jenkins CA, Lau B, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses 2016; 32:50-58.
4. Kim DJ, Westfall AO, Chamot E, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr 2012; 61:600-605.
5. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808.
6. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-1830.
7. Ota T. CCR5: a novel player in the adipose tissue inflammation and insulin resistance? Adipocyte 2013; 2:99-103.
8. Kitade H, Sawamoto K, Nagashimada M, et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 2012; 61:1680-1690.
9. Díaz-Delfin J, Domingo P, Giralt M, Villarroya F. Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. Cytokine 2013; 61:808-815.
10. MacInnes A, Lazzarin A, Di Perri G, et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials 2011; 12:24-36.
11. Pérez-Martínez L, Perez-Matute P, Aguilera-Lizarraga J, et al. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). J Antimicrob Chemother 2014; 69:1903-1910.
12. Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R. Oral preexposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010; 5:e15257.
13. Bashan N, Dorfman K, Tarnovscki T, et al. Mitogen-activated protein kinases, inhibitory-kappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. Endocrinology 2007; 148:2955-2962.
14. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420:333-336.
15. Himes SR, Sester DP, Ravasi T, et al. The JNK are important for development and survival of macrophages. J Immunol 2006; 176:2219-2228.
16. Mooney RA. Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007; 102:816-818.
17. Pedersen BK and MA Febbraio. Point: interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007; 102:814-816.
18. Febbraio MA. gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 2007; 117:841-849.
19. López-Yoldi M, Moreno-Aliaga MJ, Bustos M. Cardiotrophin-1: a multifaceted cytokine. Cytokine Growth Factor Rev 2015; 26:523-532.
20. Iñiguez M, Berasain C, Martinez-Anso E, et al. Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. J Exp Med 2006; 203:2809-2815.
21. Berraondo B, Marti A, Duncan JS, Trayhurn P, Martinez JA. Up-regulation of muscle UCP2 gene expression by a new beta3-adrenoceptor agonist, trecadrine, in obese (cafeteria) rodents, but down-regulation in lean animals. Int J Obes Relat Metab Disord 2000; 24:156-163.
22. Pérez-Matute P, Perez-Echarri N, Martinez JA, Marti A, Moreno-Aliaga MJ. Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-alpha. Br J Nutr 2007; 97:389-398.
23. Alexopoulos N, Katritsis D, Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis 2014; 233:104-112.
24. Choi Y, Jang S, Choi MS, Ryoo ZY, Park T. Increased expression of FGF1-mediated signaling molecules in adipose tissue of obese mice. J Physiol Biochem 2016; 72:157-167.
25. Park YS, Uddin MJ, Piao L, et al. Novel role of endogenous catalase in macrophage polarization in adipose tissue. Mediators Inflamm 2016; 2016:8675905.